| 000 | 01713 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250511182234.0 | ||
| 264 | 0 | _c19921110 | |
| 008 | 199211s 0 0 eng d | ||
| 022 | _a0278-0232 | ||
| 024 | 7 |
_a10.1002/hon.2900100305 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLiang, R | |
| 245 | 0 | 0 |
_aIntensive chemotherapy for peripheral T-cell lymphomas. _h[electronic resource] |
| 260 |
_bHematological oncology _c |
||
| 300 |
_a155-61 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aBleomycin _xadministration & dosage |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 |
_aDexamethasone _xadministration & dosage |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aDoxorubicin _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunophenotyping |
| 650 | 0 | 4 |
_aLeucovorin _xadministration & dosage |
| 650 | 0 | 4 |
_aLymphoma, T-Cell, Peripheral _xclassification |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMethotrexate _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPrednisone _xadministration & dosage |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 |
_aVincristine _xadministration & dosage |
| 700 | 1 | _aTodd, D | |
| 700 | 1 | _aChan, T K | |
| 700 | 1 | _aChiu, E | |
| 700 | 1 | _aLie, A | |
| 700 | 1 | _aHo, F C | |
| 700 | 1 | _aLoke, S L | |
| 773 | 0 |
_tHematological oncology _gvol. 10 _gno. 3-4 _gp. 155-61 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/hon.2900100305 _zAvailable from publisher's website |
| 999 |
_c1389617 _d1389617 |
||